Suven Life sciences secures patent from EPO

Hyderabad, Jan 9 (UNI) Suven Life Sciences has secured a Patent from European Patent Office (EPO) on Novel Serotonin Receptor Ligands and treatment of Disorders associated with Neuro-degenarative diseases.

Suven Chief Executive Officer Venkat Jasti said EPO had issued the patent '1517909 titled Novel Tetracyclic Arylcarbonylindoles having Serotonin Receptor affinity useful as therapeutic agents, process for their preparation and Pharmaceutical compositions containing them'' to Suven.

The patent was valid till June 2023, a company release said here today.

The granted claims of the patent, include class of selective 5-HT compounds discovered by Suven and developed as therapeutic agents, which were useful in the treatment of cognitive impairment associated with neuro-degenarative disorders like Attention deficient hyperactivity, Alzheimer's, Parkinson, Schizophrenia and Huntington's.

Mr Venkat said Suven would continue to work on G-Protein coupled receptor (GPCR) targets to discover and develop molecules focusing on CNS disorders with unmet medical need and high market potential, the release added.

UNI